INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisystemic disorder involving several autoantibodies with a potential etiopathogenic role, such as anti-dsDNA, antiphospholipid, and anti-SSA (Ro). Likewise, impairment of clearance of immune complexes and apoptotic cells has been considered as an important factor contributing to the development of the disease. Moreover, deficiency of complement components has also been classically associated with the development of SLE. One case of this type is homozygous C1q deficiency (1). complement in SLE (2) (3) (4) (5) , as well as in other connective tissue diseases (6,7) and hepatitis C infection (7) . Nevertheless, in SLE their presence has been associated with disease activity, particularly renal flares of lupus nephritis (5, 8, 9) . The role of C1q in clearance of apoptotic cells and immune complexes is the probable mechanism linking its deficiency or inhibition with autoimmune diseases (10, 11) .
The aim of this study was to investigate the frequency of anti-C1q antibodies in a group of Brazilian SLE patients and evaluate their association with different clinical features of the disease.
MATERIALS AND METHODS

Patient Enrollment
Unselected SLE patients were collected from a lupus referral outpatient clinic in Salvador, Brazil. The diagnosis of SLE was based on the ACR criteria (12) . Disease activity was evaluated by SLEDAI (13) . Patients infected with Virus C hepatitis were not included in the study.
Proteinuria was defined as 500 mg/24 hr or higher in the last 10 days, renal dysfunction as any increase in creatinine value at any time in the history, and renal involvement as any of the two above variables. Other clinical features were labeled if present at any time in the course of the disease.
The study had the approval of the Ethics Review Board of our institution and each patient signed a consent form on enrollment.
Laboratory Procedures
Aliquots of sera were stored at À201C until needed and all autoantibody testing was performed at the Laboratory of Molecular Biology, Gonc -alo Muniz Foundation, Bahia, Brazil. This included an autoantibody analysis by indirect immunofluorescence on HEp-2 substrate (ANA) and Crithidia luciliae (antidsDNA). Antibodies to nucleosome were measured by enzyme-linked immunoassay (ELISA) (INOVA Diagnostics Inc., San Diego, CA).
Anti-C1q antibodies by ELISA: An ELISA kit was used to detect anti-C1q as follows. Patient samples were diluted 1/100 and then added to each well. After a 30-min incubation, the wells were washed with highionic-strength buffer to remove immunoglobulins bound to the globular head region of C1q, leaving behind specific anti-C1q antibodies. Then horseradish peroxidase coupled to anti-human IgG conjugate supplied with the kit was used as the secondary antibody. After developing the reaction with the chromogen supplied, the absorbance was read at 450 nm. Values o20 U were considered as negative, and positives were classified as ''weak'' (20-39 U), ''moderate'' (40-80 U), and ''strong'' (480 U) as suggested by the manufacturer.
Statistical Analysis
All clinical and laboratory data were entered into and extracted from SPSS for Windows (version 14.0). Some results were expressed as mean7standard deviation. The Kolmogorov-Smirnov was utilized to test the normality of the variables. The Mann-Whitney test was used to compare means. Correlation coefficient was investigated by Spearman test. The association between qualitative variables was evaluated by Yates' w 2 with correction or Fisher's exact test, when indicated, considering Po0.05 as statistically significant.
RESULTS
SLE Demographics and Main Clinical Features
The unselected SLE population studied included 80 (98.7%) women and only 1 (1.3%) man with a mean age of 34 (711) years. The median disease duration was 49 months (range 2-384). The distribution of race was 40.7% Mulatto, 29.6% Caucasoid, and 29.6% Black ( Table 1 ). The main clinical features of the studied population are presented in Table 2 .
Clinical and Serological Correlate of Anti-C1q Antibodies
When the ELISA method was used to detect anti-C1q antibodies in the SLE sera, a prevalence of 39.5% (32/81) was observed. The comparative clinical and laboratory data for anti-C1q-positive and anti-C1q-negative patients are presented in Table 3 . This correlation refers to the presence of the manifestation at the time of visit or in the preceding 10 days as defined by the SLEDAI criteria.
The presence of anti-C1q antibodies was associated with proteinuria in the last 10 days, defined as higher than 500 mg/24 hr (P 5 0.028). This association was stronger when one considers proteinuria at any time in the history (P 5 0.01). In addition, there was a positive correlation between the titers of anti-C1q antibodies and the SLEDAI score (r 5 0.370; P 5 0.001) and the mean SLEDAI score was higher in the anti-C1q-positive group (P 5 0.008). On the other hand, there was no association with any of the clinical parameters such as arthritis, malar rash, mucosal ulcers, cutaneous vasculitis, pleuritis, urinary casts, hematuria, renal failure, fever, leukopenia, thrombocytopenia, presence of antinucleosome, anti-dsDNA antibodies, or lower levels of C3 or C4 of the complement cascade. Notably, there was no correlation between the titers of antinucleosome and anti-C1q antibodies (r 5 0.170; P 5 0.129).
DISCUSSION
In this study, a prevalence of 39.5% of anti-C1q antibodies was found in Brazilian SLE patients. If one takes into consideration only those with proteinuria higher than 500 mg/24 hr in the last 10 days the frequency of anti-C1q increases to 59%. This figure is similar to that observed by Sinico et al., who found anti-C1q antibodies in 27 of 61 (44%) SLE patients, and in 60% of patients with lupus nephritis, when compared with only 14% of SLE patients without nephropathy (Po0.05) (5).
Curiously enough, although an association of antiC1q and proteinuria identified in the last 10 days was found, as well as a positive correlation with SLEDAI score, no association of these antibodies was found with renal dysfunction, classified as any increase in creatinine value in the present or in the past. It may suggest that the detection of anti-C1q antibodies is a marker for disease activity, particularly in a renal site. On the other hand, the authors were unable to demonstrate any association of anti-C1q with anti-dsDNA or antinucleosome antibodies. Although similar results were observed in some studies (8, 14) , others found discordant results. correlation with the SLEDAI score, they did not find association with lupus nephritis. It is still intriguing how antibodies to C1q could cause renal disease in SLE. An indirect evidence for the role of these antibodies in the pathogenesis of lupus nephritis is the observation by Chen et al. who found higher titers of anti-C1q in patients with lupus nephritis and C1q deposition in the kidney tissue (16) . Other reasonable explanations would be that the autoantibodies inhibit the removal of apoptotic cells secondary to complement deficiency induced by these antibodies; they block the clearance of C1q-containing immune complexes, allowing them to deposit in the glomeruli, or they activate the complement cascade and consequently the inflammatory process (17) (18) (19) (20) .
On the other hand, the presence of anti-C1q antibodies has also been identified in the serum of patients with other connective tissue diseases without renal involvement or even in the normal population (21) . Thus, the possibility that these antibodies may represent only an epiphenomenon cannot be entirely excluded. However, studies in animal models have suggested that anti-C1q may amplify complement activation, that is, when a monoclonal anti-C1q antibody alone was administered to mice, it was unable to cause renal damage, but if the level of C1q was increased in glomerulus by the previous interaction of other antibodies with glomerular antigens, the mice presented renal damage (19, 20) . These observations may suggest that in SLE, different from other conditions, anti-C1q antibodies have the potential to cause renal damage. The observation in this study, of no association between antinucleosome and anti-C1q antibodies, has been corroborated by others (22) . In a previous study no association was found between antinucleosome and disease activity in SLE (23) . Thus, these two antibodies seem to identify different subsets of SLE patients.
In conclusion, this study in Brazilian SLE patients confirms previous findings of the association of anti-C1q antibodies with nephritis and disease activity. Hence, the detection of such antibodies in SLE seems to be a useful tool for the management of these patients.
ACKNOWLEDGMENTS
This work was supported by Grant 304713/2002-3 (M.G.R) by Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico (CNPq). M.S. is currently receiving a scholarship from Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico (CNPq) and FIDEPS. Rufus Burlingame is an employee and Senior Scientist of INOVA Diagnostics Inc., San Diego, CA.
